Clinicopathological characteristics of EBV+ nodal T- and NK-cell lymphoma
| . | EBV+ nodal T- and NK-cell lymphoma . | P∗ . | ||
|---|---|---|---|---|
| All cases N = 22 (n [%]) . | TET2 mutations . | |||
| Present n = 15 (n [%]) . | Absent n = 7 (n [%]) . | |||
| Age at diagnosis (median [range]), y | 68 (21-83) | 68 (40-83) | 59 (21-75) | .037 |
| Age at diagnosis, >60 y | 16/22 (73) | 14/15 (93) | 2/7 (29) | .004 |
| Sex (male/female) | 14/8 | 8/7 | 6/1 | .19 |
| Performance status score of >1 | 10/19 (53) | 8/13 (62) | 2/6 (33) | .35 |
| Clinical stage Ⅲ/Ⅳ | 19/22 (86) | 15/15 (100) | 4/7 (57) | .023 |
| B symptoms present | 11/18 (61) | 8/11 (73) | 3/7 (43) | .33 |
| Extranodal involvement at >1 site | 1/22 (5) | 1/15 (7) | 0/7 (0) | 1.0 |
| IPI high-intermediate/high | 15/20 (75) | 13/14 (93) | 2/6 (33) | .014 |
| Platelets <130 × 10⁹/L | 15/20 (75) | 11/13 (85) | 4/7 (57) | .29 |
| Serum LDH level greater than normal | 19/21 (90) | 14/14 (100) | 5/7 (71) | .10 |
| Morphology | ||||
| Centroblastoid | 14/22 (64) | 11/15 (73) | 3/7 (43) | .34 |
| Pleomorphic | 6/22 (27) | 2/15 (13) | 4/7 (57) | .054 |
| Mixed | 2/22 (9) | 2/15 (13) | 0/7 (0) | 1.0 |
| Immunophenotype | ||||
| Cytotoxic molecules | 21/22 (95) | 14/15 (93) | 7/7 (100) | 1.0 |
| CD4 | 2/21 (10) | 2/15 (13) | 0/6 (0) | 1.0 |
| CD5 | 4/20 (20) | 2/13 (15) | 2/7 (29) | .59 |
| CD8 | 15/21 (71) | 12/15 (80) | 3/6 (50) | .29 |
| CD56 | 2/22 (9) | 0/15 (0) | 2/7 (29) | .091 |
| nPD-L1 | 3/22 (14) | 0/15 (0) | 3/7 (43) | .023 |
| miPD-L1 | 10/22 (45) | 7/15 (47) | 3/7 (43) | 1.0 |
| TFH cell marker† | 3/20 (15) | 2/14 (14) | 1/6 (17) | 1.0 |
| ICOS | 1/22 (5) | 1/15 (7) | 0/7 (0) | 1.0 |
| PD-1 | 3/22 (14) | 2/15 (13) | 1/7 (14) | 1.0 |
| T-cell type‡ | 20/20 (100) | 14/14 (100) | 6/6 (100) | - |
| . | EBV+ nodal T- and NK-cell lymphoma . | P∗ . | ||
|---|---|---|---|---|
| All cases N = 22 (n [%]) . | TET2 mutations . | |||
| Present n = 15 (n [%]) . | Absent n = 7 (n [%]) . | |||
| Age at diagnosis (median [range]), y | 68 (21-83) | 68 (40-83) | 59 (21-75) | .037 |
| Age at diagnosis, >60 y | 16/22 (73) | 14/15 (93) | 2/7 (29) | .004 |
| Sex (male/female) | 14/8 | 8/7 | 6/1 | .19 |
| Performance status score of >1 | 10/19 (53) | 8/13 (62) | 2/6 (33) | .35 |
| Clinical stage Ⅲ/Ⅳ | 19/22 (86) | 15/15 (100) | 4/7 (57) | .023 |
| B symptoms present | 11/18 (61) | 8/11 (73) | 3/7 (43) | .33 |
| Extranodal involvement at >1 site | 1/22 (5) | 1/15 (7) | 0/7 (0) | 1.0 |
| IPI high-intermediate/high | 15/20 (75) | 13/14 (93) | 2/6 (33) | .014 |
| Platelets <130 × 10⁹/L | 15/20 (75) | 11/13 (85) | 4/7 (57) | .29 |
| Serum LDH level greater than normal | 19/21 (90) | 14/14 (100) | 5/7 (71) | .10 |
| Morphology | ||||
| Centroblastoid | 14/22 (64) | 11/15 (73) | 3/7 (43) | .34 |
| Pleomorphic | 6/22 (27) | 2/15 (13) | 4/7 (57) | .054 |
| Mixed | 2/22 (9) | 2/15 (13) | 0/7 (0) | 1.0 |
| Immunophenotype | ||||
| Cytotoxic molecules | 21/22 (95) | 14/15 (93) | 7/7 (100) | 1.0 |
| CD4 | 2/21 (10) | 2/15 (13) | 0/6 (0) | 1.0 |
| CD5 | 4/20 (20) | 2/13 (15) | 2/7 (29) | .59 |
| CD8 | 15/21 (71) | 12/15 (80) | 3/6 (50) | .29 |
| CD56 | 2/22 (9) | 0/15 (0) | 2/7 (29) | .091 |
| nPD-L1 | 3/22 (14) | 0/15 (0) | 3/7 (43) | .023 |
| miPD-L1 | 10/22 (45) | 7/15 (47) | 3/7 (43) | 1.0 |
| TFH cell marker† | 3/20 (15) | 2/14 (14) | 1/6 (17) | 1.0 |
| ICOS | 1/22 (5) | 1/15 (7) | 0/7 (0) | 1.0 |
| PD-1 | 3/22 (14) | 2/15 (13) | 1/7 (14) | 1.0 |
| T-cell type‡ | 20/20 (100) | 14/14 (100) | 6/6 (100) | - |
IPI, International Prognostic Index; LDH, lactate dehydrogenase; miPD-L1, microenvironmental PD-L1; nPD-L1, neoplastic programmed cell-death ligand 1.
TET2 mutations present vs absent.
All of the evaluable 20 cases were negative for CD10 and BCL6, and all 22 evaluable cases were negative for CXCL13.
Patients with T-cell type showed positivity for TCR protein expression and/or TCRγ rearrangement.